David Brown

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib:  A Potent and Selective Inhibitor of COX-2

John J. Talley, David Brown, Jeffery S. Carter et al. · Journal of Medicinal Chemistry · 2000 · 642 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +14

<i>N</i>-[[(5-Methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium:  A Potent and Selective Inhibitor of COX-2 for Parenteral Administration

John J. Talley, Stephen R. Bertenshaw, David Brown et al. · Journal of Medicinal Chemistry · 2000 · 211 citations · Full text

Pharmaceutical Science, Altmetric Attention Score, Pharmacotherapy +19

Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations

Tawanda Gumbo, Arnold Louie, Weiguo Liu et al. · Antimicrobial Agents and Chemotherapy · 2007 · 161 citations · Full text

Pharmacotherapy, Antimicrobial Chemotherapy, Antibiotic Resistance +21

Studies of Stemona alkaloids. Total synthesis of (+)-croomine

David R. Williams, David Brown, John W. Benbow · Journal of the American Chemical Society · 1989 · 134 citations

Medicine, Chemical Derivative, Altmetric Attention Score +9

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of<i>Mycobacterium tuberculosis</i>in the Log Phase of Growth

Tawanda Gumbo, Arnold Louie, Weiguo Liu et al. · The Journal of Infectious Diseases · 2006 · 101 citations · Full text